盟科药业2025年预亏2.4亿，单一产品依赖问题凸显

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. is expected to incur a loss of 240 million yuan in 2025, marking several consecutive years of unprofitability [1] Financial Performance - The company reported total revenue of 142 million yuan, representing a year-on-year increase of 8.83% [1] - The net profit and net profit excluding non-recurring items are projected to be losses of 242 million yuan and 250 million yuan, respectively [1] Product and Revenue Dependency - Currently, the company has only commercialized one product, the Kanti Zuoan tablets, leading to limited revenue growth [1] - The company had previously warned about the risks associated with reliance on a single product in its prospectus, and the actual situation aligns with these warnings [1] Future Financing and Strategy - Despite revenue growth from 2022 to 2024, it remains insufficient to cover research and commercialization expenses [1] - The company planned to raise 1.032 billion yuan by issuing shares to Hai Jing Pharmaceutical in September 2025, but this was terminated due to opposition from major shareholders [1] - The company aims to support its development through various financing channels and optimize cost control to ensure resources are prioritized for key areas [1]